Teva's makeover is real. Much of it is already priced in.

On September 1st Teva, the Israeli drugmaker, announced that its executives would present at Morgan Stanley, J.P. Morgan and Bank of America investor conferences this month. Announcements of this kind are usually filter material: the corporate equivalent of a booking in a diary. In Teva's case the diary entry is the interesting document, because the roadshow has become the product. For three years management, led by its chief executive Richard Francis, has tried to persuade investors that the world's biggest maker of generic drugs is really a "biopharma" — a company with medicines that carry the pricing power that copies lack. The pitch has been working, at a price. The shares have climbed to a market value of about $44bn, roughly eighteen times the earnings analysts expect this year. The question is what, exactly, the current price is paying for.

Start with the business Teva is trying to leave behind. Generic drugs are economics without a moat: a pill has no brand loyalty, any approved manufacturer may sell it, and the buyer — a pharmacy-benefit manager, a wholesaler, a government — shops on price alone. Prices fall every year, so the only durable advantage is cost. About half of Teva's revenue still comes from such copies, and its history shows why rents in this business are fleeting. Its old fortune, Copaxone, a treatment for multiple sclerosis, lost its patent to challengers years ago. Its recent one was a windfall: a generic version of Celgene's blood-cancer drug Revlimid that Teva sold with little competition. That bonanza is fading now; in the second quarter generics revenue fell 15% year on year, a decline the company attributes mainly to the fading of its generic Revlimid business.

The growth story meant to replace those rents is real in the numbers Teva reported on July 29th. Austedo, a drug for movement disorders and its flagship, grew 40% globally, with U.S. sales of $676m in the quarter; Ajovy, a migraine injection, rose 56% to $244m globally; Uzedy, a long-acting schizophrenia injection, grew 43% to $77m. The company raised its full-year sales guidance for all three.

The headline result of the quarter — adjusted earnings of two cents a share — looked like a catastrophe, and offers a lesson in how this company now does business. In June Teva completed the acquisition of Emalex Biosciences for $700m in cash, plus up to $200m in milestones. Emalex's asset of note is ecopipam, a pill for Tourette's syndrome close to filing with the US drug regulator. Because its value is research rather than products, the outlay is booked as an immediate expense: a $724m write-off that lopped 61 cents off the quarter's earnings. Set that aside, and the underlying result was about 63 cents a share, slightly better than expected — hence the shares' 11.5% jump on the day. The deal, in a single transaction, shows both how the pivot works, by buying near-approval science, and how it is paid for, out of operating cash.

It also shows the constraints. Buying innovation is a way to acquire rents; it is not a way to invent them cheaply, and the balance sheet sets a ceiling on ambition. Teva still owes opioid-settlement payments of $379m this year and $364m next, and finished the quarter with net debt of $12.9bn — one reason Fitch restored its investment-grade rating only in May, and one reason every dollar must choose between debt reduction, dividends and new drugs at once. Within that budget, $700m is a toe-dip, not the kind of bet that transforms a drug company.

Add what the portfolio says about where Teva sits in the industry's value chain. Its best asset is a patent rent with a clock: under a settlement with Lupin, generic rivals may first enter Austedo's market in April 2033 — far off, but a fixed date, which is why the drug must compound into a franchise before the clock runs. And in obesity, the industry's grand new rent and a market dominated by two innovators, Teva participates as the copyist: in August 2025 it won approval for the first generic GLP-1 weight-loss drug. It will earn a margin on the commodity end of modern medicine's biggest prize; the prize itself belongs to others.

The decisive question is whether the market has now paid for all of this. Teva's own guidance for 2026 — earnings of $1.91–2.11 a share — would be a fall from adjusted earnings of about $2.92 in 2025, as the Revlimid windfall fades and purchases bite. The growth on offer is 2027, when brokers' consensus puts earnings near $3.03 a share, a rise of more than half. That assumes the operating margin reaches 30% in 2027, a target the company reaffirmed at its strategy day in May 2025. The road to it runs, in part, through the ordinary machinery of cost-cutting: roughly 3,000 jobs, about 8% of the workforce, have been earmarked for elimination. AInvest, a service that aggregates signals into a rating, labels the stock a Buy even as its own measure of Teva's fundamentals scores near the bottom of its scale; the label says more about the mood than about the math.

None of this makes the September appearances trivial. They are where Teva will defend its two big promises — an operating margin of 30% by 2027 and per-share earnings near $3 — before the banks that help set the industry's opinion. The tests are concrete: whether Austedo's growth compounds into a franchise, whether ecopipam becomes a launch in 2027, whether the decline in the generics half of the business slows. No slide deck can settle them. The structural irony is that Teva is now doing two things at once — building the businesses that carry pricing power and outrunning the deflation of the commodity business that pays for them. The share price already assumes the first wins. That is the difference between a story and a discovery, and it is the one distinction worth carrying out of any conference.